The genomic landscape of AITL is characterized by mutation of epigenetic modifiers. This gene expression pattern resembles myeloid diseases and shows a potential role for hypomethylating agents as possible therapy for AITL.
Keywords: DNMT3A; TET2; angioimmunoblastic T‐cell lymphoma; epigenetic modifiers; myeloid malignancies.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.